To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/27 cls
Actelion Ltd. (SIX:ATLN) UBS Guillaume van Renterghem Upgrade Buy (from neutral) 2% $46.00
van Renterghem also adjusted his target to CHF56 from CHF57 to reflect what he sees as the equally probable scenarios for the Phase III SERAPHIN

Read the full 652 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE